Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study

NCT00522015 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT00522015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00522015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Unknown status
Start date
February 29, 2008
Completion date
February 28, 2010
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, progressive supranuclear palsy